

We Care About Making Better Therapeutics

At BIOVECTRA, we're ready and eager to turn our client's vision into a therapeutic reality.

We proactively invest in our technology and facilities, with a team that exceeds expectations for quality and professionalism at every step. From clinical-to-commercial scale production, we add efficiency and remove stress, keeping our clients' programs on track and powering towards commercialization.



Scope and Scale

BIOVECTRA is a North American CDMO specializing in clinical-to-commercial scale production.

50+

years of experience



630+

employees



100+

active clients across five geographic markets




5 state-of-the-art cGMP facilities and **3** R&D labs


18 out of the 20 top global biopharmaceutical companies supported

Aligning Our Strengths with Client Needs

Our Expertise




Biologics – We leverage the power of microbial fermentation, often coupled with our synthetic chemistry expertise, to solve complex problems and create biopharmaceuticals that improve patient health. Our 8,000+ m² facility holds two 17,000 L fermenters and a 12,000 L refolding tank, with a 1.4 m column chromatography capacity as well as two state-of-the-art single-use fermenters (100 and 1,000 L).




Synthetic Small Molecules – BIOVECTRA embraces small molecule projects from INDs through clinical trials and commercial supply of APIs for a wide variety of complex chemistries, including custom lipids, MPEGs, nanoparticles, and linkers.



pDNA & mRNA – Our Biomanufacturing Center is opening its doors to execute your pDNA, mRNA, and LNP product needs. Our capacity to produce 70 million standard mRNA vaccine doses annually for commercial distribution reflects our expanded modalities' versatility, power, and scope at preclinical and commercial scales.



Highly Potent APIs – We meet demand for high-potency APIs, including ADC warheads, with our extensive process development and production experience. Our team excels at managing complex products requiring specific handling, conjugation, or specialized processing, employing industrial hygiene monitoring practices with exceptionally low occupational exposure limits (OELs <20 ng/m³).



Bioreagents – We offer high-quality bioprocessing reagents, including cGMP grade options, to supply our customers with industry-leading quality and compliance for both research and manufacturing operations. Our multi-scale organic synthesis facility boasts a 50-1000-gallon reactor scale capable of manufacturing products at a gram to multi-kg scale.

New Dedicated Biomanufacturing Center

In late 2023, we're opening the doors on our new North American vaccine and biomanufacturing center. Located in Charlottetown, PE this state-of-the-art facility will boast:

- 36,000 square feet of new, state of the art manufacturing space
- cGMP-compliant facilities
- Manufacturing capabilities for nucleic acids (mRNA and pDNA)
- LNPs formulation capability
- Vaccine and therapeutic production capacity for 160 million doses per year
- Fill/finish capacity for 70 million doses per year for commercial distribution
- 125 highly skilled staff members dedicated to nucleic acid product manufacturing



Expanded Manufacturing Capacity with Single-Use Microbial Fermentation Technology

BIOVECTRA is accepting projects for its new, single-use biologics fermentation suite.

Containing 100 L and 1,000 L single-use fermenters, this state-of-the-art process train provides clients with a number of benefits including:

- Greater flexibility & faster turnaround times
- Increased capacity utilization
- Decreased risk of contamination
- Elimination of time-consuming and costly cleaning and sterilization between batches

Why BIOVECTRA

First-Rate Infrastructure – We pair world-class facilities and high-capacity equipment with robust and refined production standards. Through this, we support small-batch, pilot, clinical, and commercial production scales at all stages of biopharmaceutical manufacturing.

Trusted Efficiency – For 50+ years, we have delivered products and services of exceptional caliber on time and on budget. Our core foundation in microbial fermentation has allowed us to hone unparalleled efficiency in development and increase speed-to-market rates.

A CDMO With Extensive Microbial Fermentation Experience

BIOVECTRA's microbial fermentation capabilities include both single-use and stainless-steel fermenters allowing BIOVECTRA to support your biologics projects at a large variety of scales.

- State-of-the-art 100 L and 1,000 L single-use fermenters
- 3,000 L self-contained, closed, stainless steel fermenter
- Two 17,000 L self-contained, closed, stainless steel fermenters - ideal for large-scale production

We can support your tech transfer and optimization, early and mid-stage clinical investigation, and even commercial-scale supply of highly specialized therapeutics, including recombinant proteins, plasmid DNA, antibody fragments, and other biologic molecules produced in microbial systems.




- Single quality system across all manufacturing sites
- Compliant with ICHQ7, Q10
- A strong record of successful inspections

We Care About Optimizing Synthetic Small Molecule APIs

For more than 50 years, BIOVECTRA has assisted clients with small molecule projects from investigational new drug (IND) applications through clinical trials and commercial supply, providing phase-appropriate solutions. We focus on delivering clinical trial scale product quantities while addressing scale-up requirements and long-term manufacturing options that address key cost of goods (COGs) targets.

- 3 cGMP facilities with network of scales from 1 kg to 200 MT
- Specialized chemistries such as:
 - MPEG derivatives
 - Lipids
 - ADC payloads
 - Efficient purification solutions for complex molecules
- Commercial supply record of 20+ years

Our Facilities



WE CARE ABOUT

FINDING FLEXIBLE SOLUTIONS

PUSHING BOUNDARIES IN INNOVATION

EMBODYING QUALITY IN EVERYTHING

Our Team Cares About Your Success

"Flexibility is built into our DNA and it's the key to our long-term relationships. We have the ability and dedication to solve our clients' complex problems, no matter what it takes."

Andrew Mitchell
Senior Director of Business Development

"We're very collaborative with our clients, and we've strengthened our internal collaboration capabilities, increasing our accountability to each other - improving our ability to advance projects seamlessly."

Lesley Whitlock
Director, Capital Projects

"At BIOVECTRA, we've been in business for more than 50 years. We know how crucial it is to understand a client's specific needs upfront, so that we're designing the process to meet that need and delivering a consistent, quality product."

Ankur Deshpande
Director, Process Development Quality